Efficacy of upadacitinib vs dupilumab for moderate-to-severe atopic dermatitis: analysis of time spent in itch response state from the Heads Up study

被引：0
|
作者：
Blauvelt, Andrew [1 ]
de Bruin-Weller, Marjolein [2 ]
Kwatra, Shawn G. [3 ]
Gooderham, Melinda J. [4 ]
Kim, Brian [5 ,6 ,7 ,8 ]
Liu, Yingyi [9 ]
Chu, Alvina D. [9 ]
Ofori, Sarah [9 ]
Platt, Andrew [9 ]
Calimlim, Brian M. [9 ]
Silverberg, Jonathan, I [10 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR USA
[2] Univ Med Ctr Utrecht, Dept Dermatol & Allergol, Utrecht, Netherlands
[3] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[4] Queens Univ, Kingston, ON, Canada
[5] Icahn Sch Med Mt Sinai, Kimberly & Eric J Waldman Dept Dermatol, New York, NY USA
[6] Icahn Sch Med Mt Sinai, Mark Lebwohl Ctr Neuroinflammat & Sensat, New York, NY USA
[7] Icahn Sch Med Mt Sinai, Precis Immunol Inst, New York, NY USA
[8] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY USA
[9] AbbVie Inc, N Chicago, IL USA
[10] George Washington Univ, Sch Med & Hlth Sci, Dept Dermatol, Washington, DC USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 190卷
关键词：
upadacitinib; dupilumab; atopic dermatitis; moderate-to-severe; pruritus;
D O I：
10.1093/bjd/ljad498.031
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
526
引用
收藏
页码：II28 / II29
页数：2
相关论文
共 50 条
  • [41] An Observational Study of Early Treatment Response and Predictors of Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis
    Deng, Sisi
    Wang, Huan
    Fu, Jiong
    Zhai, Zhifang
    Chen, Qiquan
    Song, Zhiqiang
    DERMATOLOGIC THERAPY, 2024, 2024
  • [42] Network meta-analysis on the efficacy and safety of upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis
    Qiu, Mei
    Duan, Xue-Yan
    Yin, Dao-Gen
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2022, 61 (01) : E24 - E26
  • [43] DUPILUMAB REDUCES ITCH IN CHILDREN WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS AGED 6 MONTHS TO 5 YEARS
    Paller, A. S.
    Siegfried, E. C.
    Yosipovitch, G.
    Kwatra, S. G.
    Praestgaard, A.
    Prescilla, R.
    Wang, J.
    VALUE IN HEALTH, 2023, 26 (06) : S57 - S58
  • [44] Dupilumab Reduces Itch in Children with Moderate-to-Severe Atopic Dermatitis Aged 6 Months to 5 Years
    Paller, Amy S.
    Siegfried, Elaine C.
    Yosipovitch, Gil
    Kwatra, Shawn G.
    Praestgaard, Amy
    Wang, Zhixiao
    Prescilla, Randy
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB151 - AB151
  • [45] EFFICACY AND SAFETY OF DUPILUMAB TREATMENT UP TO 1 YEAR IN INFANTS AND PRESCHOOL CHILDREN WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Cork, Michael J.
    Paller, Amy S.
    Siegfried, Elaine C.
    Xiao, Jing
    Prescilla, Randy
    Dubost-Brama, Ariane
    Bansal, Ashish
    ACTA DERMATO-VENEREOLOGICA, 2023, 103 : 53 - 53
  • [46] SAFETY AND EFFICACY OF DUPILUMAB IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: AN ANALYSIS OF UP TO 100 WEEKS (LIBERTY AD OLE)
    Herranz, Pedro
    de la Cueva, Pablo
    Rodriguez Marco, Ainara
    Worrell, Richard
    Shumel, Brad
    INTERNAL MEDICINE JOURNAL, 2021, 51 : 25 - 25
  • [47] SAFETY AND EFFICACY OF DUPILUMAB IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: AN ANALYSIS OF UP TO 100 WEEKS (LIBERTY AD OLE)
    Roh, Joo Young
    Park, Chun Wook
    Kim, Kyu Han
    Lee, Joo Hee
    Sun, Xian
    Rossi, Ana B.
    Shumel, Brad
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 53 - 53
  • [48] Rapid response to dupilumab treatment in children with moderate-to-severe atopic dermatitis: A case series
    Votto, Martina
    Delle Cave, Francesco
    De Filippo, Maria
    Marseglia, Alessia
    Marseglia, Gian Luigi
    Brazzelli, Valeria
    Licari, Amelia
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2022, 33 : 31 - 33
  • [49] Efficacy, Safety, and Early Relapse After Cessation of Upadacitinib Versus Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Real-World Study in China
    Zhu, Jiling
    Wu, Hanwen
    Ye, Yahui
    Xu, Qiuyang
    Shao, Junyi
    Bai, Zicheng
    Zhou, Yiwen
    Li, Zhenyan
    Liu, Jingjing
    Li, Zhiming
    DERMATITIS, 2024, 35 (06) : 636 - 645
  • [50] Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year
    Andrew Blauvelt
    Marjolein de Bruin-Weller
    Eric L. Simpson
    Zhen Chen
    Marius Ardeleanu
    Ana B. Rossi
    Dermatology and Therapy, 2022, 12 : 9 - 13
12345